This histogram enumerates side effects from a completed 2017 Phase 2 trial (NCT02269943) in the CC-486 200 mg ARM group. Side effects include: Nausea with 100%, Neutropenia with 50%, Diarrhoea with 50%, Fatigue with 50%, Vomiting with 50%.
1 Treatment Group
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: CC-486 · No Placebo Group · Phase 1
Dose EscalationExperimental Group · 2 Interventions: CC-486, Duvelisib · Intervention Types: Drug, Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: at 3 and 12 months
Who is running the clinical trial?
Secura Bio, Inc.Industry Sponsor
8 Previous Clinical Trials
275 Total Patients Enrolled
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
489 Previous Clinical Trials
123,340 Total Patients Enrolled
3 Trials studying Leukemia, Lymphocytic
112 Patients Enrolled for Leukemia, Lymphocytic
Hayder Saeed, MDPrincipal InvestigatorMoffitt Cancer Center
1 Previous Clinical Trials
1 Total Patients Enrolled
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Patients must have progressed after at least two line of therapy with no available options that would provide clinical benefit per investigator discretion
Patients must have measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI).
You are 18 years of age or older.\n
You have adequate organ and marrow function as defined in protocol.
The man must take at least 93 days of appropriate contraception after the last dose of study treatment.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.